Daiichi Sankyo 9-Month Profit Almost Triples After Settlement

Daiichi Sankyo Co., the worst performer on Japan’s Topix Pharmaceutical Index last year, said nine-month profit almost tripled from a year earlier, when net income was eroded by a provision to settle a legal dispute.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.